Live Attenuated Influenza Vaccine As a Nasal Model for Influenza Infection
Who is this study for? Patients with Influenza
What treatments are being studied? Flumist Quadrivalent Nasal Product
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
The purpose of this study is to develop a nasal model for influenza infection using the live attenuated influenza vaccine (LAIV). The investigators will administer LAIV to healthy adult volunteers in order to simulate influenza infection, and obtain nasal specimens to measure influenza virus and inflammatory/immune responses. In a subset of participants, cystic fibrosis transmembrane conductance regulator (CFTR) function will also be evaluated via measurement of nasal potential difference (NPD)
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 49
Healthy Volunteers: t
View:
• ages 18-49 years old,
• not yet received influenza vaccine for 2019-2020, and
• capable of giving signed informed consent.
Locations
United States
Alabama
UAB Lung Health Center
RECRUITING
Birmingham
Contact Information
Primary
David LaFon, MD
dlafon@uabmc.edu
205-934-0266
Time Frame
Start Date: 2020-09-01
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 25
Treatments
Other: open label
FLUMIST QUADRIVALENT 0.2 mL dose supplied in a single-dose pre-filled intranasal sprayer
Related Therapeutic Areas
Sponsors
Leads: University of Alabama at Birmingham